ENTITY
Eli Lilly & Co

Eli Lilly & Co (LLY US)

175
Analysis
Health CareUnited States
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company's products are sold in countries around the world. Eli Lilly's products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
more
bullishEdding Group
15 Dec 2020 23:39

Eddingpharm: First Impressions

Eddingpharm plans to list on the HKEX. This Insight analyzes the company's products and pipeline. The main question is whether enthusiasm for the...

Share
10 Dec 2020 20:06

Cansino Biologics Placement - Past Deal Didn't Do Well, Losing the Vaccine Race

Lilly Asia is looking to raise around US$180m via selling a 6% stake in CanSino Biologics Inc (6185 HK)'s  H-shares. Lilly Asia last sold its stake...

Logo
410 Views
Share
01 Dec 2020 09:34

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

This article analyzed Harbour's core products, team, technology platforms, thoughts on valuation and the "hidden" value that is often easy to be...

Logo
324 Views
Share
13 Oct 2020 09:53

China Healthcare Weekly (Oct.9)

This insight summarized the important industry viewpoints, news of listed healthcare companies and capital market review for the last week of China...

Logo
238 Views
Share
17 Sep 2020 01:38

JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure

$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...

Logo
451 Views
Share
x